(CPXX) (CPXX) Stock Price, News & Analysis

Company Overview

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Key Stats

• Today's Range: $30.24 to $30.24
• 50-Day Range: N/A
• 52-Week Range: $1.12 to $30.36
• Volume: N/A
• Average Volume: 2.62 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CPXX Stock Analysis - Frequently Asked Questions

How were (CPXX)'s earnings last quarter?

(CPXX) (NASDAQ:CPXX) announced its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01.

What other stocks do shareholders of (CPXX) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (CPXX) investors own include Sophiris Bio (SPHS), Consolidated Water (CWCO), Anavex Life Sciences (AVXL), Alder Biopharmaceuticals (ALDR), Fc Global Realty (FCRE), Chipotle Mexican Grill (CMG) and Immunomedics (IMMU).

Company Calendar

• Last Earnings: 5/10/2016
• Today: 8/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CPXX
• CIK: 1327467
• Web: N/A
• Phone: +1-609-2430123
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A